Among tumour-infiltrating T cells and M2 macrophages (those macrophages that decrease inflammation and encourage tissue repair) in patients with localized and metastatic prostate cancer treated with ipilimumab, VISTA, PD-1 and PD-L1 have been shown to be co-upregulated. Here, PDCD1 is linked to neoplasm.